Literature DB >> 11342649

Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1.

A Alfsen1, P Iniguez, E Bouguyon, M Bomsel.   

Abstract

As one of the initial mucosal transmission pathways of HIV (HIV-1), epithelial cells translocate HIV-1 from apical to basolateral surface by nondegradative transcytosis. Transcytosis is initiated when HIV-1 envelope glycoproteins bind to the epithelial cell membrane. Here we show that the transmembrane gp41 subunit of the viral envelope binds to the epithelial glycosphingolipid galactosyl ceramide (Gal Cer), an alternative receptor for HIV-1, at a site involving the conserved ELDKWA epitope. Disrupting the raft organization of the Gal Cer-containing microdomains at the apical surface inhibited HIV-1 transcytosis. Immunological studies confirmed the critical role of the conserved ELDKWA hexapeptide in HIV-1 transcytosis. Mucosal IgA, but not IgG, from seropositive subjects targeted the conserved peptide, neutralized gp41 binding to Gal Cer, and blocked HIV-1 transcytosis. These results underscore the important role of secretory IgA in designing strategies for mucosal protection against HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11342649     DOI: 10.4049/jimmunol.166.10.6257

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  63 in total

Review 1.  Cholesterol, lipid rafts, and disease.

Authors:  Kai Simons; Robert Ehehalt
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

2.  Immunogenicity of HIV virus-like particles in rhesus macaques by intranasal administration.

Authors:  Luigi Buonaguro; Maria Tagliamonte; Maria Luisa Visciano; Hanne Andersen; Mark Lewis; Ranajit Pal; Maria Lina Tornesello; Ulf Schroeder; Jorma Hinkula; Britta Wahren; Franco M Buonaguro
Journal:  Clin Vaccine Immunol       Date:  2012-03-29

3.  Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody.

Authors:  Daniela Tudor; Huifeng Yu; Julien Maupetit; Anne-Sophie Drillet; Tahar Bouceba; Isabelle Schwartz-Cornil; Lucia Lopalco; Pierre Tuffery; Morgane Bomsel
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-20       Impact factor: 11.205

4.  Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.

Authors:  L Diomede; S Nyoka; C Pastori; L Scotti; A Zambon; G Sherman; C M Gray; M Sarzotti-Kelsoe; L Lopalco
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

Review 5.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

Review 6.  The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Authors:  Marinieve Montero; Nienke E van Houten; Xin Wang; Jamie K Scott
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

7.  Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B.

Authors:  Sang-Moo Kang; Qizhi Yao; Lizheng Guo; Richard W Compans
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

8.  Roles of fragment crystallizable-mediated effector functions in broadly neutralizing antibody activity against HIV.

Authors:  Ali Danesh; Yanqin Ren; R Brad Jones
Journal:  Curr Opin HIV AIDS       Date:  2020-09       Impact factor: 4.283

9.  Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens.

Authors:  Sang-Moo Kang; Lizheng Guo; Qizhi Yao; Ioanna Skountzou; Richard W Compans
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles.

Authors:  Hongtao Zhang; Yujun Huang; Raja Fayad; Gregory T Spear; Liang Qiao
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.